Close Menu
    Trending
    • IGEL Reaches Unicorn Status with Strategic Investment from Vitruvian Partners to Accelerate Growth of its Endpoint Security and Cyber Resilience Endpoint Platform for Enterprise
    • Booking Holdings Unveils Booking Partner Division to Accelerate B2B Travel Innovation
    • Ebola adds 60 cases in a day as Congo deaths hit 5,568
    • Dubai Airports expects over 70 million guests in 2026
    • Rand slips toward R17 as inflation and weak growth cloud outlook
    • Sinopec Co-Hosts Final of Youth Cultural Ambassador Competition in Algiers
    • Sokin expands in the UAE with DFSA license, local AED payment rails and accounts
    • Tencent Cloud Powers HooLive to Deliver Enhanced Digital Entertainment Experiences in Saudi Arabia
    • Home
    • Contact Us
    Irani TimesIrani Times
    Wednesday, November 18
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Irani TimesIrani Times
    Home » Ad Scientiam Launches International Study to Assess Disability Progression in Multiple Sclerosis With MSCopilot
    ACCESS Newswire

    Ad Scientiam Launches International Study to Assess Disability Progression in Multiple Sclerosis With MSCopilot

    September 12, 2023
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    PARIS, FRANCE / ACCESSWIRE / September 12, 2023 / Ad Scientiam, a global leader in digital biomarkers, has announced a partnership with Sanofi to launch MS-DETECT, an international, multicenter, longitudinal study. MS-DETECT aims to evaluate the ability of MSCopilot®, a medical software device, to detect early signs of disability worsening in people with multiple sclerosis (PwMS). The study will draw upon Ad Scientiam’s expertise in MS and is financially supported by Sanofi.

    AdS logo
    AdS logo

    Multiple Sclerosis (MS) is a chronic immune-mediated disease of the central nervous system that affects 2.8 million people worldwide. The disease is characterized by early inflammatory demyelination and subsequent neurodegeneration. Current clinical evaluation of PwMS relies mainly on the Expanded Disability Status Scale (EDSS), which has several limitations. To improve on these assessments, Ad Scientiam has developed MSCopilot®, a software medical device that addresses four dimensions: ambulation/mobility, upper extremity function, cognition, and low-contrast visual acuity.

    MS-DETECT’s main objective is to determine MSCopilot®’s ability to identify subtle and early disability worsening. This will be performed by evaluating MSCopilot® individual and/or composite scores as compared to the Multiple Sclerosis Functional Composite (MSFC) and the EDSS.

    “MS-DETECT is a pioneering large-scale longitudinal study that explores digital biomarkers for the early detection of disease progression. This study will provide important data to both clinicians and people living with MS,” according to Dr. Saad Zinaï, Chief Medical Officer at Ad Scientiam.

    “Disability worsening in MS has been recently redefined and we now know that this progression can occur independently of relapses. With MS-DETECT, we have an opportunity to develop a digital solution to help detect and monitor the effects of smoldering disease, and evolve treatment goals for MS patients,” explains Su-Peing Ng, Global Head of Medical Affairs – Specialty Care at Sanofi.

    The study also aims to assess the MSCopilot® performance, safety, usability and satisfaction with the solution.

    “Disease progression can be hard to detect in routine practice. I believe these novel digital biomarkers are key to help clinicians make appropriate treatment decisions and, ultimately, improve patients’ care,” said Prof. Patrick Vermersch (Lille, France), Coordinating Investigator and Chairman of the Study Steering Committee.

    The MS-DETECT study will include 314 PwMS and will be conducted in the United States, Canada, Germany, Italy, Spain, Denmark and France. Several investigative sites have already been initiated in North America and Europe and first patients are expected to participate in the study during Q3 2023.

    Check our LinkedIn, Facebook, Instagram pages or visit adscientiam.com

    Contact Information

    Saad Zinaï
    Chief Medical Officer
    szinai@adscientiam.com
    +33768008666

    Matthieu Lamy
    President
    mlamy@adscientiam.com
    +33768008666

    SOURCE: Ad Scientiam

    View source version on accesswire.com:
    https://www.accesswire.com/782728/ad-scientiam-launches-international-study-to-assess-disability-progression-in-multiple-sclerosis-with-mscopilot

    Related Posts

    Chevron Signs 3-Year Agreement with UptimeAI, Scaling Expertise to Enhance Asset Reliability and Operational Efficiency

    November 17, 2026

    Pitches and Keynote Speakers Are Confirmed for Blue Magic Netherlands on November 17

    November 4, 2026

    Chervon Names Jody Grimsley Senior National Account Manager

    November 2, 2026

    GA-ASI and Saab Perform Advanced AEW Flight Testing on Uncrewed MQ-9B

    October 28, 2026

    Chervon Names Parker Wesley Clary Director of Field Sales – Southern Division

    October 26, 2026

    Study Finds Lower Rates of Overweight Among Vegan-Fed Cats

    October 23, 2026
    Latest News

    Ebola adds 60 cases in a day as Congo deaths hit 5,568

    November 18, 2026

    Dubai Airports expects over 70 million guests in 2026

    November 18, 2026

    Rand slips toward R17 as inflation and weak growth cloud outlook

    November 18, 2026

    Over 9 million visitors lift Tunisia tourism income 3.4%

    November 17, 2026
    © 2026 Irani Times | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.